Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SOD1 | P00441 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16059015 | 1.00 | MAOB (0.39) | MAOBHSD17B10HTTRAB9AL3MBTL1 | |
| SCHEMBL19548837 | 1.00 | MAOB (0.39) | MAOBHSD17B10HTTRAB9AL3MBTL1 | |
| SCHEMBL6490888 | 0.84 | CYP2D6 (0.43) | HSD17B10ALDH1A1KMT2AKDM4ELMNA | |
| SCHEMBL16059615 | 0.80 | LPL (0.36) | — | |
| SCHEMBL17499035 | 0.80 | APLNR (0.34) | — | |
| SCHEMBL16059627 | 0.77 | ALDH1A1 (0.44) | MAOBHSD17B10ALDH1A1KMT2AKDM4E | |
| SCHEMBL16058602 | 0.77 | ALDH1A1 (0.44) | MAOBHSD17B10ALDH1A1KMT2AKDM4E | |
| SCHEMBL12488618 | 0.75 | ALDH1A1 (0.46) | MAOBHSD17B10HTTL3MBTL1ALDH1A1 | |
| SCHEMBL24156424 | 0.74 | APLNR (0.35) | SOD1 | |
| SCHEMBL27083524 | 0.74 | APLNR (0.35) | SOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416263-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-12-28 | — | — | US | disclosed |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20210155631-A1 | CARM1 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10633389-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190135819-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-05-09 | — | — | US | disclosed |
| US-10118931-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2018-11-06 | — | — | US | disclosed |
| US-20180282343-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2018-10-04 | — | — | US | disclosed |
| US-20170320883-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2017-11-09 | — | — | US | disclosed |
| US-9738651-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155631-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | MAOB 2971/4885HSD17B10 1662/4885HTT 1394/4885 |
| US-10118931-B2 | CARM1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | MAOB 2971/4885HSD17B10 1662/4885HTT 1394/4885 |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | MAOB 2971/4885HSD17B10 1662/4885HTT 1394/4885 |
| US-20170320883-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | MAOB 2992/4885HSD17B10 1685/4885HTT 1409/4885 |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | MAOB 2992/4885HSD17B10 1685/4885HTT 1409/4885 |
| US-10633389-B2 | CARM1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | MAOB 2971/4885HSD17B10 1662/4885HTT 1394/4885 |
| US-20190135819-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | MAOB 2971/4885HSD17B10 1662/4885HTT 1394/4885 |
| US-20230416263-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | MAOB 2971/4885HSD17B10 1662/4885HTT 1394/4885 |
| US-20180282343-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | MAOB 2992/4885HSD17B10 1685/4885HTT 1409/4885 |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | MAOB 3024/4885HSD17B10 1906/4885HTT 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.